Filing Details
- Accession Number:
- 0001140361-14-026658
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2014-06-25 17:25:46
- Reporting Period:
- 2014-06-23
- Filing Date:
- 2014-06-25
- Accepted Time:
- 2014-06-25 17:25:46
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1302573 | Oncomed Pharmaceuticals Inc | OMED | Pharmaceutical Preparations (2834) | 383572512 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1297000 | Denise Pollard-Knight | C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2014-06-23 | 52,797 | $24.20 | 2,070,010 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2014-06-24 | 11,764 | $23.57 | 2,058,246 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Footnotes
- The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
- Sales prices range from $23.56 to $24.45 per share, inclusive.
- The shares of common stock of OMED are owned by Phase4 Ventures III LP ("Phase4"). The Reporting Person is a partner of Phase4 Partners Limited, which is the manager of Phase4. The Reporting Person disclaims beneficial ownership of the reported securities held by Phase4 except to the extent of her pecuniary interest therein.
- Sales prices range from $23.55 to $23.63 per share, inclusive.